Latest Industry Insights
Industry Insight
From Hits to Leads: Improving Early Drug Discovery With Better Tools
In this interview, Dr. Iain Yisu Wang from MedChemExpress discusses the growing role of AI, the value of phenotypic screening and how tailored compound libraries are helping researchers keep up with the increasing complexity of drug discovery.
Industry Insight
AI and Synthetic Biology: Balancing Innovation With Biosecurity
AI is revolutionizing biotechnology innovation, but industry stakeholders must work together to mitigate its risks. In this article, Adam Clore explores the role of nucleic acid biosecurity screening tools and how they can be improved.
Industry Insight
From Policy to Practice: How Human-Based In Vitro Models Are Reshaping Discovery
Discover how scalable, human-based in vitro models are reshaping discovery pipelines, balancing complexity with reproducibility, and enabling new kinds of experimentation that go beyond the limits of animal research.
Industry Insight
From Bench to Boardroom: Leading Cell and Gene Therapy Through Uncertainty
In this opinion piece, Dr. Stella Vnook explores how cell and gene therapy leaders are adapting to today’s financial and regulatory headwinds, offering actionable insights into how biotech CEOs are rethinking capital strategy.
Industry Insight
Driving Innovation While Navigating Global Pressures: How One Life Science Company Is Evolving With the Market
As global scientific and regulatory landscapes shift, companies across the life sciences sector are under growing pressure to adapt. Hear how Phenomenex are taking a proactive approach.
Industry Insight
Life Science Marketing: All You Need To Know
This article explores the unique characteristics and challenges of life sciences marketing, offering insights on how to achieve meaningful engagement with a highly specialized audience.
Industry Insight
A New Era in Drug Discovery Begins as FDA Embraces Human Models
In this article, discover how the FDA and NIH are replacing animal testing with human models, such as organoids, featuring expert insights on safer, faster and ethical drug development.
Industry Insight
FDA Delays Cell and Gene Therapy Approvals Following CMC Issues
Explore why cell and gene therapy manufacturing failures are now a leading cause of FDA rejections and how to avoid them.
Industry Insight
Beyond Black-Box Models: Advances in Data-Driven ADMET Modeling
Discover how AI-powered ADMET modeling can enable the prediction of toxicity and pharmacokinetics with depth, transparency and scientific rigor.
Industry Insight
Are Plans To Phase Out Animal Testing Realistic?
Cell models are replacing animal testing in pharma. Explore expert tips on transitioning to more accurate, ethical and scalable alternatives.
Advertisement